Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM3 | Q86V86 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | MAPT | P10636 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.31 |
| ▸ | LMNA | P02545 | 3/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25534915 | 0.95 | TDP1 (0.32) | PIM3MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL25535205 | 0.94 | MAPT (0.32) | MEN1MAPTKMT2AALDH1A1HPGD | |
| SCHEMBL25534990 | 0.92 | MEN1 (0.34) | MEN1MAPTKMT2AALDH1A1HPGD | |
| SCHEMBL25535073 | 0.90 | MEN1 (0.33) | PIM3MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL25535135 | 0.90 | MEN1 (0.34) | PIM3MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL25534906 | 0.89 | ALDH1A1 (0.32) | MEN1MAPTKMT2AALDH1A1HPGD | |
| SCHEMBL20647394 | 0.89 | MEN1 (0.33) | PIM3MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL20647404 | 0.89 | MEN1 (0.33) | PIM3MEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL25535189 | 0.89 | MEN1 (0.39) | MEN1MAPTKMT2AALDH1A1HPGD | |
| SCHEMBL25535202 | 0.89 | ALOX5 (0.39) | MEN1MAPTKMT2AALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167072-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
| US-20230167072-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | IDEMITSU KOSAN CO.,LTD. (JP) | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167072-A1 | COMPOUND, MATERIAL FOR ORGANIC ELECTROLUMINESCENT ELEMENTS, ORGANIC ELECTROLUMINESCENT ELEMENT, AND ELECTRONIC DEVICE | PIEZO1, LEF1, L1CAM | PIM3 3340/4885MEN1 267/4885MAPT 1595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.